51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC acquired a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 51,133 shares of the company’s stock, valued at approximately $379,000. Campbell & CO Investment Adviser LLC owned approximately 0.08% of Monte Rosa Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in shares of Monte Rosa Therapeutics in the 2nd quarter worth $48,000. Lazard Asset Management LLC boosted its holdings in Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares during the last quarter. Prudential Financial Inc. bought a new stake in Monte Rosa Therapeutics in the 2nd quarter worth about $54,000. Sei Investments Co. purchased a new stake in Monte Rosa Therapeutics in the 2nd quarter valued at about $74,000. Finally, Wealth Effects LLC bought a new position in shares of Monte Rosa Therapeutics during the 3rd quarter worth approximately $75,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Stock Down 5.0%

NASDAQ GLUE opened at $23.02 on Friday. The company’s 50 day moving average is $17.94 and its 200-day moving average is $10.94. Monte Rosa Therapeutics, Inc. has a 12-month low of $3.50 and a 12-month high of $25.77. The firm has a market cap of $1.50 billion, a P/E ratio of 71.94 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.06. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%.The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $7.37 million. Equities analysts expect that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total transaction of $128,396.34. Following the completion of the transaction, the chief executive officer owned 618,937 shares of the company’s stock, valued at $14,538,830.13. The trade was a 0.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

GLUE has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Guggenheim upped their price objective on Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Jefferies Financial Group reissued a “buy” rating and issued a $31.00 price target on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Finally, TD Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.